Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACTS Dr José de Chastonay Chief Marketing Officer Bachem Holding AG Markus Schwaller Business Development Manager Bachem AG ADDRESS Hauptstrasse 144 4416 Bubendorf Switzerland TELEPHONE +41 61 935 2323 FAX +41 61 935 2325 EMAIL sales.ch@bachem.com YEAR FOUNDED 1971 Bachem www.bachem.com FINANCIAL SUMMARY 1. Half-Year Year 2012 2011 Sales (in MCHF) 76.2 145.8 EBITDA (in MCHF) 19.8 33.2 EBIT in % of sales 13.9% 10.2% Net income (in MCHF) 7.1 9.4 Net income in % of sales Earnings per share 9.3% 6.5% (EPS – in CHF) Number of employees 0.53 0.70 (in full-time equivalents) 649 671 COMPANY PROFILE Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides. MANAGEMENT Board of Directors Dr h.c. Peter Grogg, Honorary Chairman Dr Kuno Sommer, Chairman Dr Thomas Burckhardt, Secretary Nicole Grogg Hötzer Dr Jürgen Brokatzky-Geiger Prof Dr Hans Hengartner Dr Rolf Nyfeler Corporate Executive Commitee Dr Thomas Früh, CEO Stephan Schindler, CFO Dr Daniel Erne, CTO Dr José de Chastonay, CMO t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACT Mr Richard Godfrey Chief Executive Officer ADDRESS BerGenBio AS Jonas Lies vei 91 5009, Bergen, Norway TELEPHONE +47 917 86 304 EMAIL Richard.Godfrey@bergenbio.com YEAR FOUNDED 2009 BerGenBio AS www.bergenbio.com FINANCIAL SUMMARY Private Company: – Revenue generating – VC funded – Series A 2011 $10m Investors: • Sarsia Seed Fund • Investinor Fund Capital plans: – Series B Q4 2012. COMPANY PROFILE BerGenBio`s mission is to develop novel therapeutics against emerging targets for advanced cancer. The company has a deep understanding of the tumor microenvironment and mechanisms of action that result in epithelial-to-mesenchymal transition (EMT), the formation of cancer seeding (stem) cells and drug resistance. The company is built on proprietary CellSelect technology platform used to identify and validate novel drug targets and de-risk and accelerate the development of novel therapeutic candidates. BerGenBio has a pipeline of clinical and preclinical candidates. The company is simultaneously developing biomarker and PD assays as companion diagnostics for its pipeline of drug leads. With its headquarters in Bergen Norway, BerGenBio has established a fully integrated in vitro & in vivo research and development infrastructure and a drug discovery and clinical development team in UK. PIPELINE BGB324 First in class, highly selective Axl inhibitor. Poised to enter Ph1 Q1`13. BGB109 mAb inhibitor of Axl. Preclinical candidate at LO stage BGB002 Undisclosed target, discovery stage TECHNOLOGIES CellSelectRNAi Identify novel targets missed by other methods CellSelectImaging in vivo & in vitro imaging and recovery of cells CellSelectScreening High throughput in vitro assays and screening CellSelectModeling Advanced in-vitro and in-vivo models CellSelectRegulated Genetic dose response treatment/disease models MANAGEMENT Prof James Lorens, CSO – (James.Lorens@bergenbio.com) Dr David Micklem, CTO – (David.Micklem@bergenbio.com) Dr Longen Zhou, Director of Cancer Biology t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3 and 4: Events Diary For regular updates, s
Page 5 and 6: Speakers Alexey Eliseev, Managing D
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33: CONTACT Carina Schmidt Chief Execut
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86:
CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88:
ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90:
CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92:
CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94:
CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96:
CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98:
CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100:
CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?